Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Account Payables (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Change in Account Payables for 7 consecutive years, with -$3.3 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 321.59% to -$3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, up 193.7% year-over-year, with the annual reading at $6.8 million for FY2025, 193.7% up from the prior year.
  • Change in Account Payables hit -$3.3 million in Q4 2025 for Eton Pharmaceuticals, down from $2.1 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $7.3 million in Q2 2025 to a low of -$3.3 million in Q4 2025.
  • Historically, Change in Account Payables has averaged $430050.0 across 5 years, with a median of $11500.0 in 2022.
  • Biggest five-year swings in Change in Account Payables: plummeted 1033.09% in 2021 and later skyrocketed 5688.46% in 2025.
  • Year by year, Change in Account Payables stood at -$1.3 million in 2021, then skyrocketed by 156.11% to $712000.0 in 2022, then crashed by 85.25% to $105000.0 in 2023, then soared by 1311.43% to $1.5 million in 2024, then crashed by 321.59% to -$3.3 million in 2025.
  • Business Quant data shows Change in Account Payables for ETON at -$3.3 million in Q4 2025, $2.1 million in Q3 2025, and $7.3 million in Q2 2025.